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    D u e  t o  t h e  t h e r a p e u t i c  p o t e n t i a l  o f  g e n e  t h e r a p y  f o r  
neuronal  injury,  many  studies  of  neurotrophic  factors, 
vectors,  and  animal  models  have  been  performed.  The 
presumed  dog  β-nerve  growth  factor  (pdβ-NGF)  was 
generated and cloned and its expression was confirmed in 
CHO cells. The recombinant pdβ-NGF protein reacted with 
a human β-NGF antibody and showed bioactivity in PC12 
cells. The pdβ-NGF was shown to have similar bioactivity to 
the dog β-NGF. The recombinant pdβ-NGF plasmid was 
administrated into the intrathecal space in the gene therapy 
group. Twenty-four hours after the vector inoculation, the 
gene therapy group and the positive control group were 
intoxicated  with  excess  pyridoxine  for  seven  days.  Each 
morning throughout the test period, the dogs’ body weight 
was taken and postural reaction assessments were made. 
Electrophysiological recordings were performed twice, once 
before the experiment and once after the test period. After 
the experimental period, histological analysis was performed. 
Dogs in the gene therapy group had no weight change and 
were normal in postural reaction assessments. Electrophysio-
logical recordings were also normal for the gene therapy 
group. Histological analysis showed that neither the axons 
nor the myelin of the dorsal funiculus of L4 were severely 
damaged in the gene therapy group. In addition, the dorsal 
root ganglia of L4 and the peripheral nerves (sciatic nerve) 
did not experience severe degenerative changes in the gene 
therapy group. This study is the first to show the protective 
effect of NGF gene therapy in a dog model. 
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Introduction 
  There are many studies on the treatment of neuronal injuries. 
Among them, gene therapy has the potential to be important 
in pathological responses to injury and to the enhancement 
of functional recovery [1,5,8,20,21]. 
  For gene therapy of neuronal injury, various neurotrophic 
factors, vectors, and animal models need to be considered. 
Most of the previous studies on neuroprotective gene 
transfer used genetically engineered virus vectors, such as 
the herpes-simplex type Ι virus and the adenovirus [6-8,17, 
20]. Among the various neuropathies of the nervous system, 
peripheral neuropathies are characterized by motor, 
sensory, and sympathetic deficits. Sensory neuropathies are 
frequently associated with diabetes, anticancer therapies, 
and metabolic disorders [4,9]. Various drugs have been used, 
such as cisplatin, taxol, and acrylamide for the induction of 
sensory neuropathies [4,14]. There are many neurotrophic 
factors for gene therapies, such as nerve growth factor 
(NGF), and the brain-derived neurotrophic factor, 
neurotrophin-3 [11]. Nerve growth factor is one of the 
growth factors now being recognized as essential to the 
survival and maturation of sensory and sympathetic 
neurons, along with other neurotrophins [16]. NGF consists 
of three subunits, α, β, and γ, and forms a 7S complex of 
approximately 27 kDa. This complex contains two identical 
118 amino acid β chains that are solely responsible for the 
trophic activity of NGF [19]. Although a specific role for β-NGF 
in the adult peripheral nervous system has not been 
established, there are many studies concerning the effect of 
β-NGF in animal models of peripheral neuropathy, and these 
studies have shown that β-NGF had protective effects from 
the degeneration characteristic of peripheral neuropathy in 
sensory neurons [3,10].
  In humans, there are many neurodegenerative disorders 
and there have been many trials to treat these disorders with 
neurotrophic factors [11]. In the veterinary field, many 368    Jin-Young Chung et al.
Fig. 1. The nucleotide and deduced amino acid sequence of the 
presumed dog β-NGF (pdβ-NGF) open reading frame (ORF) 
along with the primers used for cloning (underlined or boxes).
neurodegenerative disorders also exist, and more trials 
should be done to identify and characterize appropriate 
treatments. In some animals, species-specific β-NGF 
sequences, which are needed for clinical trials, have already 
been determined [2,19]. To our knowledge, this is the first 
study about the presumed function of dog β-NGF (pdβ-NGF) 
in vitro and in vivo. 
  The ultimate goal of this study was to determine the effect 
of the cytomegalovirus (CMV) vector-mediated gene 
transfer of the pdβ-NGF in vitro and gene therapy using 
recombinant pdβ-NGF plasmid in the dog model, having 
pyridoxine-induced peripheral neuropathy. 
Materials and Methods
Cloning of the presumed dog β-NGF
  Genomic DNA was extracted from the tonsil tissue of a 
healthy adult male mongrel dog using the DNeasy Tissue Kit 
(Qiagen, Germany). Primers were generated using the 
sequences of human and mouse β-NGF genes to amplify 
partial dβ-NGF sequences. PCR using the primers NGF- 1F 
(5'-TCAGCATTCCCTTGACACWG-3') and NGF-1R 
(5'-AGCCTTCCTGCTGAGCAC-3') was performed for 
35 cycles at 94
oC for 1 min, 44
oC for 1min and 72
oC for 1 
min (Fig. 1). PCR using the primers NGF-2F (5'-AGTTCT 
CGGTGTGCGACAG-3') and NGF-2R (5'-GCCCAGGA 
GAGTGTGGAG-3') was also performed for 35 cycles at 
94
oC for 1 min, 55
oC for 1 min and 72
oC for 1 min (Fig. 1). 
A PCR product of approximately 600 bp was expected when 
using the primers NGF-1F and NGF-1R and 400 bp with the 
primers NGF-2F and primer NGF-2R. Overlapping PCR was 
performed to combine the PCR products of the partial 
dβ-NGF using NGF-1F and NGF-2R. This overlap PCR was 
performed for 35 cycles at 94
oC for 1 min, 58
oC for 1 min 
and 72
oC for 1 min. The size of this PCR product was 
confirmed to be approximately 660 bp (pcDNA1) using 
1.5% agarose gel electrophoresis. The cloning of pcDNA1 
was performed with pCR2.1 vector (Invitrogen, USA) and 
plasmid DNA was extracted from Escherichia coli TOP10 
cells (Invitrogen, USA) with the plasmid purification kit 
(NucleoGen Biotechnology, Korea). The plasmids were 
sequenced by Takara-Korea Biomedical Inc. The remainder 
of dβ-NGF DNA was synthesized artificially based on the 
sequence of the predicted Canis familiaris nerve growth 
factor beta (5′-ATGTCCATGTTGTTCTACACTCTGAT 
CACAGCTCTTCTGATCGGCATCCGGGCAGAACC
GCATCCAGAGAGCCATGTCCCAGCAGGACACGC
CATCCCCCACGCCCACTGGACTAAGCTTCAGCAT
TCCCTT-3′; GeneBank sequence entry XM_540250; NCBI, 
USA) (Fig. 1). Overlapping PCR was performed to combine 
the synthesized oligonucleotide and pcDNA1. The sense 
primer (Bgl2 + NGF-F) with a sequence of 5′-GGCAGATC 
TATGTCCATGTTG- 3′, and the antisense primer (EcoR1 
+ NGF-R) with a sequence of 5′-GGAGAATTCTCAGGC 
TCGTCT-3′, were used for the overlap PCR. The sense 
primer had the BglII (TaKaRa Bio, Japan) restriction site and 
the antisense had the EcoR I (TaKaRa Bio, Japan) restriction 
site. PCR was performed for 35 cycles at 94
oC for 1 min, 53
oC 
for 1 min and 72
oC for 1 min. The obtained PCR product was 
expected to be 725 bp (pcDNA2). The pcDNA2 was cloned 
and the nucleotide sequence was analyzed. The pcDNA2 
clone was named the presumed dog β-NGF (pdβ-NGF). 
Construction of the recombinant pdβ-NGF plasmid
  The CMV vector (phCMV1; Gene Therapy Systems, USA) 
was chosen to construct the recombinant pdβ-NGF (rpdβ- 
NGF) plasmid. The phCMV vector and pcDNA2 were 
digested with Bgl II and EcoR I restriction enzymes, and 
purified following separation on a 1.5% agarose gel. Ligation 
of the purified phCMV1 and pcDNA2 was performed using 
T4 DNA ligase (TaKaRa Bio, Japan). The rpdβ-NGF plasmid 
was transformed into Escherichia coli TOP10 cells and 
DNA extracted with a plasmid purification kit.
Production of the recombinant presumed dog β-NGF
  The rpdβ-NGF plasmid and a separate phCMV1 vector 
plasmid prepared for transfection were free of protein, 
RNA and chemical contamination (A260/A280 ratio of 1.9) 
and had a final concentration of 0.4 mg/ml. 
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(Gene therapy systems, USA) was carried out to deliver the 
two plasmids into Chinese hamster ovary (CHO) cells 
(Korean Cell Line Bank, Korea). Four days after the 
transfections, supernatants were collected and filtered 
through a 0.22-μm filter (Millipore, USA).
The recombinant presumed dog β-NGF protein 
measurement and bioassay
  pdβ-NGF protein levels were measured using the Duoset 
Enzyme-Linked Immunosorbent Assay (ELISA) development 
system (R&D Systems, USA). This system used a sandwich 
ELISA method with anti-human β-NGF as the detection 
antibody and was performed according to the manufacturer’s 
recommendations. The bioactivity of the pdβ-NGF protein 
was assessed using the rat pheochromocytoma cell line 
(PC12 cell; Seoul National University, Korea). PC12 cells 
were plated at a density of 5 × 10
4 cells/ml in 24-well tissue 
culture plates (Falcon, USA). One ml of supernatant from the 
rpdβ-NGF-tranfected CHO cells was added to the PC12 cell 
cultures. Supernatant from CMV-transfected CHO cells, 
was used as a negative control. PC 12 cells were monitored 
daily by microscopic examination.
Animals
  Ten mongrel dogs (5 males and 5 females) roughly 2 years 
of age were used in this experiment. The body weights 
ranged from 4 to 6 kg. Among them, two dogs were in the 
negative control group, four dogs were in positive control 
group and four dogs were in the experimental group with 
gene therapy. All of the dogs were clinically judged to be in 
good health and neurologically normal, and had their own 
admission number from the Institute of Laboratory Animal 
Resources, Seoul National University (SNU-060623-1). 
During the experiment, all of the dogs were cared for 
according to the Animal Care and Use Guidelines (Institute 
of Laboratory Animal Resources, Seoul National University, 
Korea). Body weights of test dogs were measured every 
morning during the test period.
Gene transfection in dogs
  The CMV vector containing rpdβ-NGF was prepared in 
advance. The cationic polymer transfection reagent (Polyplus 
transfection, France) was used to transport these plasmids 
into the intrathecal region. Each plasmid was condensed 
with in vivo-jetPET-Gal reagent at a 10-N/P ratio (measure 
of the ionic balance of the complexes). First, the prepared 
plasmids were diluted with 200 μl of 5% glucose (w/v) and 
an appropriate amount of in vivo-jetPET-Gal reagent in 200 
μl of 5% glucose (w/v). Second, 200 μl of in vivo- jetPET- 
Gal solution was added to the plasmid solution followed by 
incubation for 15 min at room temperature. Third, the 
mixture was injected to the dogs of the gene therapy group 
(n = 4) through intrathecal injection using a 27-gauge 
needle. Before this administration, the dogs of the gene 
therapy group were anesthetized with zoletil.
Pyridoxine intoxication 
  Twenty-four hours after vector inoculation, the dogs from 
the gene therapy group (n = 4) and the positive control group 
(n = 4) were intoxicated with pyridoxine (Sigma, France). 
The pyridoxine was prepared in distilled water (100 mg/ml) 
immediately before injection, and administered at 150 mg/kg 
subcutaneously once a day in the morning, for 7 days. Dogs 
in the negative control group (n = 4) received vehicle (iso- 
osmotic sterile aqueous solution of sodium chloride). 
Postural reaction assessments
    Postural reaction (wheelbarrowing, hopping, extensor 
postural thrust, placing, tonic neck reaction and proprioceptive 
positioning) assessments were done on all dogs every 
morning during the test period.
Electrophysiological recordings
  All of the dogs were preanesthetized with atropine (0.1 
mg/kg of body weight, IM). Anesthesia was induced with 
diazepam and was maintained with isoflurane through a 
semiclosed system. Subcutaneous temperature was 
maintained at 37∼38
oC. Neuropack2 (Nihon Kohden, 
Japan) was used for all recordings. All measurements were 
performed in the left hindlimb. M wave was recorded for the 
tibial nerve, using 1 Hz, 0.5 ms, supramaximal stimulus. 
Stimulating electrodes were positioned in the distal tibial 
nerve. The recording electrode was positioned in the plantar 
interosseous muscle. The ground electrode was positioned 
between the stimulating electrode and the recording 
electrode. The recording electrode was a bipolar needle 
electrode. The Hoffman (H)-reflex was recorded using 1 Hz, 
0.5 ms, submaximal stimulus. The stimulating electrode 
was positioned in the tibial nerve adjacent to the hook and 
the recording and ground electrodes were positioned in the 
same site of the tibial nerve where the M wave was measured. 
All measurements were performed at least eight times. 
Electrophysiological recordings were performed twice, 
once before the experiment and once after the test period.
Morphological analyses
  After the experimental period (10 days from the start of 
the experiment), the dogs were anesthetized with a high 
dose of Tiletamine/zolazepam and propofol, and perfused 
transcardially with 0.1 M phosphate-buffered saline (PBS), 
followed by 4% paraformaldehyde in 0.1 M PBS to induce 
euthanasia. After perfusion, tissues (lumbar spinal cord 
(L4), left and right dorsal root ganglia of L4 and sciatic 
nerve) were quickly removed and post-fixed for 4∼6 h in 
the same fixative at 4
oC and embedded in paraffin. The 
tissues were sectioned serially with a thickness of 5 μm 
using a microtome (Reichert-Jung, Germany) and floated 
onto gelatine-coated slides. Next, they were deparaffinized 370    Jin-Young Chung et al.
Fig. 2. PC12 cells were cultured with and without the filtered 
supernatant and photographed at ×100 magnification. (A) 
Negative control group. (B) Experimental group with cells 
showing neurite growth. 
in xylene, rehydrated in a descending ethanol series, and 
stained with hematoxylin and eosin. The sections were 
observed using an Olympus BX51 microscope (Olympus, 
Japan) attached to a IMT2000 digital camera (iMTechnology, 
Korea) and images were captured using Adobe Photoshop 
version 6.0 software via IMT2000.
Statistical analysis 
  A Paired t-test was done for the analysis of body weights, 
M wave and H-reflex amplitudes before and after the 
pharmacologic treatment. The level of significance was set 
at p ＜ 0.05.
Results
In vitro study
  The results of nucleotide sequence analysis showed that the 
gene cloned in pcDNA1 had a high degree of sequence 
homology with other mammalian β-NGF genes. The 
pcDNA1 sequence shared 86% and 83% sequence homology 
with that of human (GeneBank sequence entry NM_ 002506; 
NCBI, USA) and mouse (GeneBank sequence entry NM_ 
013609; NCBI, USA) β-NGF sequences, respectively. The 
remaining part of dβ-NGF DNA, which was synthesized 
artificially, was included in the 5’ region of the dβ-NGF open 
reading frame (ORF) and contained 132 base pairs. 
Overlapping PCR was performed to combine the synthesized 
oligonucleotide and pcDNA1, and the obtained PCR 
product was 725 bp (pcDNA2). Again, the nucleotide 
sequence analysis showed that the cloned gene had a high 
degree of sequence homology with other mammalian 
β-NGF genes. The pcDNA2 clone was named the presumed dog 
β-NGF (pdβ-NGF) (Fig. 1). With the additional sequence 
contributed by the syntesized oligoneucleotide, the shared 
homology changed to 85% and 81% compared to human 
(GeneBank sequence entry NM_002506; NCBI, USA) and 
mouse (GeneBank sequence entry NM_013609; NCBI, 
USA) β-NGF sequences, respectively. The deduced pdβ-NGF 
amino acid sequence shared 90% and 82% homology with 
that of human (GeneBank sequence entry NM_002506; 
NCBI, USA) and mouse (GeneBank sequence entry NM_ 
013609; NCBI, USA), respectively. 
  Four days after transfection to CHO cells, pdβ-NGF protein 
was obtained from the supernatant. The filtered supernatant 
was measured with sandwich ELISA of human β-NGF. The 
results indicated that 53 pg/ml of pdβ-NGF protein existed 
in the supernatant. The bioactivity of pdβ-NGF protein 
was assessed using the rat pheochromocytoma cell line 
(PC12 cell; Seoul National University, Korea). Seven days 
after treatment with filtered supernatant, a small number of 
PC12 cells had neurite outgrowth, while the PC12 cells in 
the negative control group maintained their original 
morphology (Fig. 2).
In vivo study 
  The weight measurements showed that there was weight 
loss only in the positive control group. There were no 
weight changes in the negative control group or the gene 
therapy group. The difference in body weight of the positive 
control group was statistically significant (p ＜ 0.05). The 
differences in body weight of the negative control group 
and the gene therapy group were not statistically significant 
(p ＜ 0.05). 
  All the dogs in the positive control group developed a 
neurological disorder, characterized by ataxia involving 
first, and most prominently, the hindquarters. All of the dogs 
in the positive control group started to show proprioceptive 
abnormalities involving the hindquarters as detected by the 
postural reaction test (wheelbarrowing, hopping, extensor 
postural thrust, placing, tonic neck reaction and proprioceptive 
positioning) on the third day of pyridoxine injection. On the 
fourth day of pyridoxine injection, all dogs held their 
hindlimb stiffly when standing. These conditions were 
maintained until the end of the pyridoxine injection. On the 
other hand, all of the dogs in the negative control group and 
the gene therapy group were normal during the postural 
reaction test.
  Electrophysiological readings were recorded to measure 
M wave and H reflex in all treatment groups. The M wave 
amplitude of all the dogs in the negative control group, the 
positive control group, and the gene therapy group showed 
no remarkable change before and after the pyridoxine 
administration as confirmed by statistical analysis (p ＜ 0.05). 
However, there was a remarkable change in H reflex before 
and after the pyridoxine intoxication in the positive control 
group. Before the pyridoxine intoxication, the amplitude of 
H reflex was 0.52 ± 0.06 mV. After the pyridoxine intoxication, 
however, there was no consistently detectable H reflex in the 
positive control group. The H reflexes in the negative control 
group and the gene therapy group did not change before and 
after the pyridoxine intoxication as confirmed by statistical 
analysis (p ＜ 0.05). 
  Histopathologically, there were no lesions in the lateral, 
dorsal or ventral funiculus, or in the gray matter of L4 in the 
negative control group (Fig. 3A). The axons and myelin was Presumed dog β-NGF gene therapy in vitro and in vivo    371
Fig. 3. (A) Normal dorsal funiculus of L4 in the negative control
group. (B) Dorsal funiculus of L4, showing disruption of axons 
and myelin with vacuolation in the positive control group. (C) 
Dorsal funiculus of L4 showed occasionally swollen axons in the
gene therapy group. H&E stain, ×200.
Fig. 4. (A) Normal dorsal root ganglia (DRG) of L4 in the negative
control group. (B) DRG of L4 showed severe chromatolysis, 
vaculoation (arrowhead) and occasionally pyknotic nuclei and 
eosinophilic cytoplasm (arrows) in neurons in the positive control 
group. (C) DRG of L4 showed pyknotic nuclei and eosinophilic 
cytoplasm (arrows) in a few neurons in the gene therapy group. 
H&E stain, ×200.
Fig. 5. (A) Normal sciatic nerve of the negative control group. 
(B) Sciatic nerve having severe vacuolation (arrow) of the 
myelin in the positive control group. (C) Mild vacuolation 
(arrow) of the myelin in sciatic nerve of the gene therapy group.
H&E stain, ×400.
disrupted with vacuolation in the positive control group 
(Fig. 3B). In the gene therapy group, swollen axons were 
occasionally seen in the dorsal funiculi of L4 (Fig. 3C).
  There were no lesions in the dorsal root ganglia (DRG) of 
L4 in the negative control group (Fig. 4A). However, 
severe chromatolysis was observed in the neurons of DRG 
of L4 in the positive control group. Vacuolation was also 
observed in the neurons. Occasionally, some neurons were 
necrotic, and were characterized by pyknotic nuclei and 
eosinophilic cytoplasm (Fig. 4B). Some neurons had 
pyknotic nuclei and eosinophilic cytoplasm in the gene 
therapy group (Fig. 4C).
  There were no lesions in the axons or myelin in peripheral 
nerves (sciatic nerve) of the negative control group (Fig. 
5A). Severe vacuolation was seen in the myelin in 
peripheral nerves (sciatic nerve) of the positive control 
group (Fig. 5B). There was mild vacuolation in the myelin 
in peripheral nerves (sciatic nerve) of the gene therapy 
group (Fig. 5C). 
Discussion 
  Recently, significant efforts have been made to develop 
gene therapies in the neurologic area. For the development 
of gene therapies, the selection of appropriate growth 
factors, vectors, delivery reagents, animal models, and 
administration route are important. 
  To our knowledge, this is the first study of dog β-NGF. In 
this study, we were not able to clone the full-length ORF of 
dβ-NGF, only a partial region. We believe this is because 
NGF contents in dog tissues are low. To compensate for this, 
the remaining portion of the dβ-NGF ORF was synthesized 
artificially. To generate a functional NGF protein, it is very 
important that the correct tertiary structure is formed. For 
this reason, the CHO cell expression system was chosen 
instead of the E. coli expression system [4]. Since the 
amount of secreted proteins was small in the CHO cell 372    Jin-Young Chung et al.
expression system, only small amounts of recombinant 
proteins were obtained. The ELISA showed that 53 pg/ml 
of pdβ-NGF protein existed in the supernatant. This amount 
(53 pg/ml) by itself may not bear meaning at this stage since 
we do not know the exact ELISA cross-reactivity ratio 
between human and dog β-NGF. However, the findings are 
significant in that they indicate for the first time that the 
presumed dog’s recombinant proteins were reactive to the 
anitibody used in the human ELISA kit used in this study. 
Based on these data, it is suggested that pdβ-NGF DNA has the 
equivalent bioactivity of the dog β-NGF. Since many 
neurodegenerative disorders also exist in the veterinary 
field, there should be more trials to analyze the pathogenesis 
and to develop appropriate treatments. These clinical 
investigations require dog-specific β-NGF. The results 
obtained in this study will open the way for basic and applied 
research on dog β-NGF as a neurotrophic factor. 
  For gene transfection in an animal model, several kinds of 
vectors and transfection agents were used. Although some 
viral vectors may be efficient in transducing cells, they are 
also associated with higher biological risks. Compared 
with viral vectors, a CMV vector is very safe when used 
with animal models. Cationic liposomes, which condense 
and introduce DNA into cells, have been considered to be 
more suitable candidates for gene therapy due to their 
non-immunogenicity, non-toxicity, and relative biological 
safety [20].
  Studies on the treatments of nervous system diseases are 
very difficult because of the blood-brain barrier (BBB). 
The plasmid DNAs are not small enough to penetrate the 
BBB. Therefore, systemic injections of plasmid DNAs 
could not performed. Direct intratheral injection into the 
cisterna magna offers easy access to the intrathecal space 
and does not require surgical procedures. 
  To determine whether CMV vector-mediated gene transfer 
of pdβ-NGF can protect sensory neurons from degeneration, 
we used a model of pyridoxine intoxication in dogs. In high 
doses, pyridoxine causes a selective degeneration of large 
and small myelinated sensory axons in the central and 
peripheral nerves, resulting in numbness and loss of 
proprioception that manifests clinically as a sensory ataxia 
without weakness. The advantage of pyridoxine-induced 
neuropathy is the absence of systemic toxicity that often 
complicates analysis of treatment effect [12,13]. 
  To analyze the effects of this experiment, observations were 
made by neurological examination and electrophysiological 
recordings. After neurological examination, loss of 
proprioception without other neurologic abnormalities was 
confirmed in only the positive control group. The neurological 
examination is an earlier indicator of neurotoxicity compared 
to other tests, so it is very useful and convenient. Among the 
electrophysiological recordings, M wave and H reflex were 
tested. The muscle may have responded as a result of a 
threshold stimulus (supramaximal stimulus), applied to its 
motor fibers. Action potentials were conducted orthodromi-
cally, resulting in the M wave. The muscle potential is the 
resultant activity of a true monosynaptic reflex arc and thus 
appropriately referred to as an H reflex. The maximal H 
reflex amplitudes were obtained with submaximal stimulus 
[18]. In a previous report, we confirmed that pyridoxine- 
induced neuropathy with electrophysiological recordings 
are related only to sensory axons in the central and peripheral 
nerve [10].
    There are many trials of gene therapies in human 
neurological disorders, involving the selection of factors, 
vectors, delivery reagents, animal models and administration 
routes. In the veterinary field, especially the small animal 
neurological field, many neurodegenerative disorders also 
exist, but there are fewer studies completed. In experimental 
animals, such as mice and rats, there are many studies about 
species-specific neurotrophic factors for human medicine, 
but not for small animals. The results obtained in this study 
shall open the way for basic and applied research in 
veterinary neurologic areas. 
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